Hospital staff provide medical care for patients at a coronavirus disease (COVID-19) ward, amid a surge in new cases that has forced Israel into a second nationwide lockdown, at Tel Aviv Sourasky Medical Center (Ichilov), Tel Aviv, Israel, Sept. 21, 2020. Photo: Reuters / Ronen Zvulun.

Israel signed a deal with Pfizer on Friday to receive 8 million doses of the drugmaker’s potential COVID-19 vaccine, Prime Minister Benjamin Netanyahu said, enough to cover close to half of Israel‘s population.

Pfizer and German partner BioNTech SE confirmed a deal was forthcoming in a statement on Thursday but did not disclose financial details. There was no immediate comment from the two companies on Friday.

The agreement still requires approval by the US Food and Drug Administration (FDA) and Israel‘s Health Ministry, Israeli Health Minister Yuli Edelstein said. Pfizer is expected to apply for approval this month, he added.

Pfizer’s potential vaccine is likely to be a two-dose course of treatment, meaning that 8 million doses would cover 4 million of Israel‘s 9 million population.

In televised remarks, Netanyahu said the agreement marked “a great day for Israel,” adding, “The goal is for the vaccine supply to start in January and increase in the months thereafter”.

Pfizer on Monday announced that its experimental COVID-19 vaccine was more than 90% effective based on initial trial results, a potential major victory in the war against a virus that has killed more than a million people and battered the world economy.

In addition to its new deal with Pfizer, Israel has an agreement with Moderna for the future purchase of its potential vaccine. Moderna said on Wednesday it had enough data for a first interim analysis of the late-stage trial of its vaccine candidate.